Literature DB >> 30470404

Diffuse Low-Grade Glioma-Related Epilepsy.

Johan Pallud1, Guy M McKhann2.   

Abstract

The World Health Organization classifies diffuse low-grade gliomas (DLGGs) are highly epileptogenic primary brain tumors; epileptic seizures occur in more than 90% of cases. Epileptic seizures and drug resistance progress during the course of DLGGs. The glioma-related epileptogenic mechanisms are multifactorial; epileptogenic foci lie within the infiltrated peritumoral neocortex. A short seizure duration before surgery and a large extent of resection are the main predictors of postoperative seizure control in DLGGs. A supratotal resection of a DLGG can improve postoperative seizure control. Epileptic seizure at diagnosis positively affects DLGGs malignant transformation and overall survival.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffuse low-grade glioma; Epileptic seizure; GABA; Glutamate; Isocitrate dehydrogenase; Mammalian target of rapamycin (mTOR); Maximal functional-based resection; Surgery

Mesh:

Year:  2018        PMID: 30470404     DOI: 10.1016/j.nec.2018.09.001

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  11 in total

Review 1.  Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.

Authors:  Jasmin Jo; Martin J van den Bent; Burt Nabors; Patrick Y Wen; David Schiff
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

2.  Integrative analysis of expression profile indicates the ECM receptor and LTP dysfunction in the glioma-related epilepsy.

Authors:  Zhi-Bin Wang; Jian Qu; Pan Xie; Zhi-Quan Yang; Chen-Xue Mao; Ying Zhang; Zheng-Wen He; Zhuan-Yi Yang; Xiao-Yuan Mao; Zhao-Qian Liu
Journal:  BMC Genomics       Date:  2022-06-08       Impact factor: 4.547

3.  Predictors of early, recurrent, and intractable seizures in low-grade glioma.

Authors:  Jasmin Jo; Kathryn Nevel; Ryan Sutyla; Mark Smolkin; M Beatriz Lopes; David Schiff
Journal:  Neurooncol Pract       Date:  2020-08-29

Review 4.  Molecular Imaging of Brain Tumor-Associated Epilepsy.

Authors:  Csaba Juhász; Sandeep Mittal
Journal:  Diagnostics (Basel)       Date:  2020-12-05

5.  Non-invasively measured brain activity and radiological progression in diffuse glioma.

Authors:  T Numan; S D Kulik; B Moraal; J C Reijneveld; C J Stam; P C de Witt Hamer; J Derks; A M E Bruynzeel; M E van Linde; P Wesseling; M C M Kouwenhoven; M Klein; T Würdinger; F Barkhof; J J G Geurts; A Hillebrand; L Douw
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

Review 6.  The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome-Guided Therapeutic Attitude.

Authors:  Melissa Silva; Catalina Vivancos; Hugues Duffau
Journal:  Brain Sci       Date:  2022-04-15

7.  Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis.

Authors:  Pierre A Robe; Matea Rados; Wim G Spliet; Reinier G Hoff; Peter Gosselaar; Marike L D Broekman; Martine J van Zandvoort; Tatjana Seute; Tom J Snijders
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

8.  Clinical and Magnetic Resonance Imaging (MRI) Features, Tumour Localisation, and Survival of Dogs with Presumptive Brain Gliomas.

Authors:  Marta Pons-Sorolla; Elisabet Dominguez; Michał Czopowicz; Anna Suñol; Christian Maeso Ordás; Carles Morales Moliner; Marc Pérez Soteras; Patrícia Montoliu
Journal:  Vet Sci       Date:  2022-05-27

Review 9.  Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication.

Authors:  Sabine Seidel; Tim Wehner; Dorothea Miller; Jörg Wellmer; Uwe Schlegel; Wenke Grönheit
Journal:  Neurol Res Pract       Date:  2022-09-05

Review 10.  The Most Common Lesions Detected by Neuroimaging as Causes of Epilepsy.

Authors:  Bożena Adamczyk; Karolina Węgrzyn; Tomasz Wilczyński; Justyna Maciarz; Natalia Morawiec; Monika Adamczyk-Sowa
Journal:  Medicina (Kaunas)       Date:  2021-03-22       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.